NMN (Nicotinamide Mononucleotide)

Verdict: Suggestive Last reviewed: 2026-04-24 Triangulated against anchor: NMN (this page is the canonical anchor for "Suggestive")

TL;DR

NAD+ precursors raise blood NAD+ levels. Whether that translates into healthspan or lifespan extension in humans is unresolved. The closest precursor tested by the ITP (nicotinamide riboside, NR) failed to extend mouse lifespan. NMN's human RCTs to date have measured NAD+ levels and short-term biomarkers — not hard endpoints. Verdict: Suggestive, leaning toward downgrade if the next round of trials disappoints.

What it is

A NAD+ biosynthesis precursor in the salvage pathway. Sold as a supplement (powders, capsules, sublingual). Closely related to nicotinamide riboside (NR), nicotinamide (NAM), and nicotinic acid (niacin) — all converge on NAD+. Typical doses range from 250-1000 mg/day. Bioavailability and tissue distribution remain debated; oral NMN converts substantially to NR in the gut before absorption.

Proposed mechanism

NAD+ is a cofactor for sirtuins, PARPs, and CD38. Tissue NAD+ levels decline with age in many tissues. The proposed therapy: replenish NAD+ → restore sirtuin activity → improve mitochondrial function, DNA repair, metabolic regulation.

Confidence: Plausible. NAD+ decline with age is real and reproducible. The functional importance of restoring it via oral supplementation, at doses that meaningfully change tissue (not just blood) NAD+, is less clear. Several mechanistic claims (e.g., direct NMN transport via Slc12a8) remain contested in the literature.

Evidence ladder

Invertebrate (T5)

Lifespan extension in C. elegans and D. melanogaster reported with NAD+ precursors. Replicated, modest effects.

Mouse / rat (T4)

• ITP status (NR, the closest precursor tested): Negative. Harrison et al. 2021 (Aging Cell): NR did not significantly extend lifespan in pooled UM-HET3 data for either sex despite confirmed bioavailability (elevated serum nicotinamide). One site marginally positive in females, one site marginally negative — the kind of pattern the methodology describes as null.
• NMN itself has not been ITP-tested separately. Some single-lab studies (Mills 2016, Yoshino 2020 lineage) report healthspan biomarker improvements. Lifespan data is thin and mostly single-lab.
• Effect size: Where positive, modest biomarker improvements (mitochondrial function, glucose tolerance) without consistent lifespan extension.
• Replication: Inconsistent. The fact that NR failed at the ITP — the gold standard for replication — is the dominant data point.
• Sex / strain / dose: Heterogeneous and underpowered.

NHP (T4)

No major NHP lifespan or hard-endpoint data on NMN.

Human (T2)

Small RCTs are now numerous, but the pattern is consistent and limited:

• Yoshino et al. 2021, Science — 10-week NMN in postmenopausal women with prediabetes: improved muscle insulin sensitivity. Surrogate endpoint, small sample.
• Yamaguchi et al. 2022 — small open-label trial showing NAD+ elevation and modest functional measures.
• Multiple supplement-industry-funded RCTs — consistently show NAD+ blood level elevation; functional outcomes inconsistent and underpowered.
• No mortality, no hard endpoint, no ITP-equivalent rigor in humans.

Confounds

• Blood vs tissue NAD+ — NAD+ in blood rises with supplementation; whether this reflects tissue NAD+ in muscle, brain, or other organs is uncertain.
• Conversion to NR / NAM in the gut means oral NMN ≠ tissue NMN.
• Publication bias signal: high. The literature is dominated by industry-affiliated authors and groups with commercial interests in NAD+ products.
• Aging marker validity — many trials use biomarkers (telomere length, DunedinPACE, GlycanAge) without strong evidence those biomarkers respond to short-term interventions in ways that predict outcomes.

Conflict of interest scan

• Heavy industry involvement. David Sinclair (NMN advocate) co-founded Sirtris (sold to GSK; resveratrol commercialization), MetroBiotech (NMN). ChromaDex, Elysium are NAD+ commercializers. Many published trials have direct or indirect ties.
• Per methodology section 5: industry-funded studies without pre-registration → 1-tier discount. Most NMN human studies fit this; the effective tier of human evidence is closer to T3 than T2.
• ITP is not industry-funded → no discount on the negative ITP/NR result.

Human translation

Honestly: NMN raises blood NAD+ at high enough doses. Beyond that, the human evidence for healthspan or lifespan benefit is suggestive at best. There is no mortality data, no large hard-endpoint RCT, and the closest pharmacological cousin (NR) failed at the ITP — the most rigorous mouse lifespan testing apparatus that exists.

The popular discourse — driven in significant part by commercially conflicted advocates — treats NMN as established. The methodology forbids this. The biology is real (NAD+ decline with age happens), but the leap from "biology is real" to "supplementing with NMN extends life" is not supported at higher evidence tiers.

Calibrated verdict

Suggestive. This page is the canonical anchor for the Suggestive band. The bar for Suggestive: T3 or T4 evidence with replication, but human data absent or null. NMN sits squarely there — interesting biology, real but contested mouse data, human RCTs only on surrogates.

Compared to rapamycin (Probable), NMN lacks ITP-positive lifespan data and lacks compelling human surrogate data. Rapamycin's mouse evidence is replicated at the ITP; NMN's closest cousin failed there.

Compared to resveratrol (Mostly hype), NMN has not been definitively rejected by the ITP — NR's pooled result was null, not negative. NAD+ biology is also more central to aging than sirtuin activation by polyphenols. NMN avoids "Mostly hype" because the underlying biology is real and the field is producing new data.

If the next 2-3 years bring (a) negative results from a well-powered NMN human RCT or (b) NMN ITP testing that mirrors NR's null, NMN moves to Mostly hype.

Confidence interval on verdict

• Could move to Probable if a large, pre-registered, non-industry-funded human RCT shows healthspan benefit on a validated endpoint. Unlikely in the next 2 years.
• Could move to Mostly hype if NMN is ITP-tested and pooled data is null, or a major non-industry RCT reports null. Plausible.
• Most likely 2-year trajectory: stays at Suggestive; lean downward if industry-funded biomarker trials continue to dominate without independent confirmation.

Open questions

• Q: Will NMN itself be ITP-tested? Status?
• Q: Does oral NMN raise tissue NAD+ at physiologically meaningful levels in any organ besides liver, or is the effect mostly hepatic?
• Q: Is the apparent NAD+ decline with age tissue-specific in ways that predict who benefits from supplementation (e.g., does muscle NAD+ decline more than brain, and does that change the calculus)?
• Q: Are there any pre-registered, non-industry-funded human RCTs of NMN with hard or near-hard endpoints in progress?

Sources

• Harrison et al. 2021, Aging Cell — 17α-estradiol late in life extends lifespan in UM-HET3 male mice; NR and three other drugs do not affect lifespan in either sex (ITP)
• Yoshino et al. 2021, Science — Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
• Mills et al. 2016, Cell Metabolism — Long-term administration of NMN mitigates age-associated physiological decline in mice
• Atria Health Library — What you should know about NAD+ supplements
• GeroScience 2025 — NR treatment enhances stress sensitivity and modulates hematological dynamics in aged mice
• Springer 2022 review — Balancing NAD+ deficits with NR: therapeutic possibilities and limitations

Produced under methodology locked 2026-04-24. Anchor for the Suggestive band.